Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCTPP1 | Q9H773 | 10/20 | 0.41 |
| ▸ | SCD | O00767 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5312812 | 0.89 | SCD (0.56) | DCTPP1SCD | |
| SCHEMBL5307475 | 0.86 | CA2 (0.41) | RAB9ASMN1; SMN2GAAKDM4EALDH1A1 | |
| SCHEMBL5306153 | 0.84 | DCTPP1 (0.49) | DCTPP1SCDRAB9A | |
| SCHEMBL5370515 | 0.82 | DCTPP1 (0.46) | DCTPP1SCD | |
| SCHEMBL5306200 | 0.80 | DCTPP1 (0.50) | DCTPP1SCDALDH1A1 | |
| SCHEMBL5306130 | 0.80 | DCTPP1 (0.49) | DCTPP1SCD | |
| SCHEMBL5358417 | 0.79 | SCD (0.60) | DCTPP1SCD | |
| SCHEMBL5309091 | 0.78 | SCD (0.60) | DCTPP1SCD | |
| SCHEMBL5312323 | 0.76 | SCD (0.48) | DCTPP1SCDRAB9ASMN1; SMN2KDM4E | |
| SCHEMBL5309214 | 0.75 | SCD (0.49) | SCDSMN1; SMN2KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007046867-A2 | PIPERIDINE DERIVATIVES AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2007-04-26 | — | — | WO | disclosed |